Cathie Wood Crispr Therapeutics Ag Transaction History

Ark Investment Management LLC

$14 Billion
Q1 2024

A detailed history of Cathie Wood (Ark Investment Management LLC) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ark Investment Management LLC holds 8,157,028 shares of CRSP stock, worth $459 Million. This represents 3.97% of its overall portfolio holdings.

Number of Shares

8,157,028

Previous 8,536,104 4.44%

Holding current value

$459 Million

Previous $534 Million 4.05%

% of portfolio

3.97%

Previous 3.21%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	SELL	$60.67 - $89.12 $23 Million - $33.8 Million	-379,076 Reduced 4.44%	8,157,028 $556 Million
Q4 2023 Jan 17, 2024	BUY	$38.62 - $72.18 $53 Million - $99.1 Million	1,372,986 Added 19.17%	8,536,104 $534 Million
Q3 2023 Oct 18, 2023	SELL	$45.39 - $59.0 $7.96 Million - $10.3 Million	-175,329 Reduced 2.39%	7,163,118 $325 Million
Q2 2023 Jul 10, 2023	SELL	$43.47 - $67.77 $28.3 Million - $44.2 Million	-651,741 Reduced 8.16%	7,338,447 $412 Million
Q1 2023 Apr 17, 2023	BUY	$41.0 - $56.12 $6.57 Million - $8.99 Million	160,256 Added 2.05%	7,990,188 $361 Million

Q4 2022 Jan 24, 2023	SELL	$39.19 - $65.67 $16 Million - $26.7 Million	-407,190 Reduced 4.94%	7,829,932 $0
Q3 2022 Oct 17, 2022	SELL	$61.1 - $83.78 $91.1 Million - $125 Million	-1,490,409 Reduced 15.32%	8,237,122 $538 Million
Q2 2022 Jul 11, 2022	BUY	$43.23 - $73.83 $14 Million - $23.9 Million	323,460 Added 3.44%	9,727,531 $565 Million
Q1 2022 Apr 19, 2022	BUY	$53.19 - $79.24 $16.8 Million - $25.1 Million	316,203 Added 3.48%	9,404,071 $590 Million
Q4 2021 Jan 28, 2022	BUY	$70.09 - $111.29 $105 Million - $167 Million	1,502,194 Added 19.8%	9,087,868 $689 Million
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $21 Million - $29.8 Million	-190,445 Reduced 2.45%	7,585,674 $849 Million
Q2 2021 Aug 05, 2021	SELL	$100.84 - $161.89 $51.9 Million - $83.2 Million	-514,231 Reduced 6.2%	7,776,119 $1.26 Billion
Q1 2021 May 13, 2021	SELL	$110.72 - $210.04 $235 Million - $446 Million	-2,122,626 Reduced 20.38%	8,290,350 $1.01 Billion
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $156 Million - $339 Million	1,955,656 Added 23.12%	10,412,976 $1.59 Billion
Q3 2020 Oct 30, 2020	BUY	$78.5 - $100.64 $155 Million - $199 Million	1,974,069 Added 30.45%	8,457,320 $707 Million
Q2 2020 Aug 11, 2020	BUY	$38.5 - $76.05 $84.6 Million - $167 Million	2,197,619 Added 51.28%	6,483,251 $476 Million
Q1 2020 May 14, 2020	BUY	$33.68 - $62.53 $44.8 Million - $83.1 Million	1,328,997 Added 44.95%	4,285,632 $182 Million
Q4 2019 Jan 31, 2020	BUY	$36.68 - $73.13 $6.4 Million - $12.8 Million	174,495 Added 6.27%	2,956,635 $180 Million
Q3 2019 Nov 12, 2019	BUY	$40.99 - $52.56 $2.37 Million - $3.04 Million	57,791 Added 2.12%	2,782,140 $114 Million
Q2 2019 Jul 30, 2019	BUY	$35.45 - $48.2 $24.9 Million - $33.8 Million	701,332 Added 34.67%	2,724,349 $128 Million
Q1 2019 May 13, 2019	BUY	$28.02 - $40.87 $19.6 Million - $28.5 Million	697,907 Added 52.67%	2,023,017 $72.3 Million
Q4 2018 Feb 01, 2019	SELL	$22.73 - $42.34 $2.92 Million - $5.44 Million	-128,480 Reduced 8.84%	1,325,110 $37.9 Million
Q3 2018 Nov 07, 2018	BUY	$44.35 - $65.71 $43.7 Million - $64.8 Million	986,450 Added 211.17%	1,453,590 $64.5 Million
Q2 2018 Aug 07, 2018	BUY	$42.62 - $73.59 $16.8 Million - $29 Million	394,606 Added 544.03%	467,140 $27.4 Million
Q1 2018 May 14, 2018	BUY	$23.52 - $58.17 $967,753 - $2.39 Million	41,146 Added 131.09%	72,534 $3.32 Million
Q4 2017 Feb 12, 2018	BUY	$16.95 - $23.48 $98,869 - $136,958	5,833 Added 22.83%	31,388 $737,000
Q3 2017 Nov 09, 2017	BUY	$16.75 - $20.66 $212,172 - $261,700	12,667 Added 98.29%	25,555 $457,000
Q2 2017 Aug 11, 2017	BUY	N/A	12,888	12,888 $206,000

Others Institutions Holding CRSP

# of Institutions

551

Shares Held

56.3M

Call Options Held

2.91M

Put Options Held

2.47M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.39B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track Cathie Wood's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.

Account